Claire B. Discenza

This study develops an antibody transport vehicle targeting the transferrin receptor to improve brain delivery of anti-amyloid antibodies, reducing ARIA-like lesions and vascular inflammation in a mouse model.

This study compares the biodistribution of Fc-engineered molecules targeting BBB receptors with standard antibodies, showing distinct CNS and peripheral organ targeting.

This paper demonstrates that systemically delivered OTV, a TfR-binding molecule, effectively transports ASO across the BBB, achieving widespread and sustained knockdown of target genes in the CNS of mice and non-human primates.